Orchard Rx Ltd.
We are a commercial-stage, fully-integrated biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Our gene therapy approach seeks to transform a patient’s own, or autologous, HSCs into a gene-modified drug product to treat the patient’s disease through a single administration. We achieve this outcome by utilizing a lentiviral vector to introduce a functional copy of a missing or faulty gene into the patient’s autologous HSCs through an ex vivo process, resulting in a drug product that can then be re-introduced into the patient at the bedside.
|Industry:||BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)|
|Address||108 Cannon Street, London EC4N 6EU, United Kingdom|
|Phone Number||+44 (0) 203 384 6700|
|View Prospectus:||Orchard Rx Ltd.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-193.8 mil (last 12 months)|
|Price range||$14.00 - $14.00|
|Est. $ Volume||$200.0 mil|
|Manager / Joint Managers||J.P. Morgan/ Goldman Sachs/ Cowen|
|Expected To Trade:||10/31/2018|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|